Abstract
There has been a significant increase in people diagnosed with diabetes. It is estimated that by 2025, 300 million people worldwide will be diagnosed as diabetic. In the U.S. alone, 19.9 million people are expected to be diagnosed with diabetes by the year 2025, and 29 million cases by the year 2050. There are two types of diabetes, type 1 and type 2. Both types of diabetes are diagnosed when blood glucose levels are above normal. Both types of diabetes have serious medical sequelae including neurologic problems with neuropathies, retinopathies, kidney failure, gastroparesis, impaired wound healing, bladder control problems, erectile dysfunction, and cardiovascular complications. Given this broad spectrum of complications, research regarding modifiable risk factors is of paramount importance. Recent research has led to the important discovery of an association between sleep loss and type 2 diabetes. There are many categories of sleep disorders, though the types of sleep disorders that have been associated with type 2 diabetes include: short sleep duration, obstructive sleep apnea, insomnia, and restless legs syndrome. While requiring further exploration, this association is of great clinical significance as it may have numerous implications in both the treatment and diagnosis of both disorders. This review outlines the most cutting-edge research involving the relationship between the above sleep disorders and the risk of diabetes. What is clear from the research is that sleep of sufficient quantity and quality is essential for health and well-being, especially in those with diabetes. Sleep disorders are associated with type 2 diabetes, impairments in glucose metabolism, elevations of glucose and insulin, and insulin resistance, and may serve as a modifiable risk factor. Efforts made to improve sleep may prevent the development of these medical sequelae, though more research is needed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Van Cauter E, et al. Metabolic consequences of sleep and sleep loss. Sleep Med. 2008;9 Suppl 1:S23–8.
Boyle JP, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24(11):1936–40.
Ayas NT, et al. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med. 2003;163(2):205–9.
Gangwisch JE, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension. 2006;47(5):833–9.
Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci. 2008;1129:287–304.
Leger D, et al. Short sleep in young adults: insomnia or sleep debt? Prevalence and clinical description of short sleep in a representative sample of 1004 young adults from France. Sleep Med. 2011;12(5):454–62.
Cappuccio FP, et al. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33(2):414–20.
Gangwisch JE, et al. Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample. Sleep. 2008;31(8):1087–96.
Singh M, et al. The association between obesity and short sleep duration: a population-based study. J Clin Sleep Med. 2005;1(4):357–63.
Luckhaupt SE, Tak S, Calvert GM. The prevalence of short sleep duration by industry and occupation in the National Health Interview Survey. Sleep. 2010;33(2):149–59.
Mallon L, Broman JE, Hetta J. High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. Diabetes Care. 2005;28(11):2762–7.
Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413–37.
Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763–70.
Mullington JM, et al. Sleep loss reduces diurnal rhythm amplitude of leptin in healthy men. J Neuroendocrinol. 2003;15(9):851–4.
Spiegel K, et al. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab. 2004;89(11):5762–71.
Spiegel K, et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846–50.
Peltier AC, et al. Effect of mild hyperglycemia on autonomic function in obstructive sleep apnea. Clin Auton Res. 2011;22:1–8.
Schober AK, Neurath MF, Harsch IA. Prevalence of sleep apnoea in diabetic patients. Clin Respir J. 2011;5(3):165–72.
Aronsohn RS, et al. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med. 2010;181(5):507–13.
Pillai A, et al. Effects of sleep apnea severity on glycemic control in patients with type 2 diabetes prior to continuous positive airway pressure treatment. Diabetes Technol Ther. 2011;13(9):945–9.
Garcia JM, et al. Weight and metabolic effects of CPAP in obstructive sleep apnea patients with obesity. Respir Res. 2011;12(1):80.
Hecht L, Mohler R, Meyer G. Effects of CPAP-respiration on markers of glucose metabolism in patients with obstructive sleep apnoea syndrome: a systematic review and meta-analysis. Ger Med Sci. 2011;9:Doc20.
Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7–10.
Knutson KL, et al. Cross-sectional associations between measures of sleep and markers of glucose metabolism among subjects with and without diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Sleep Study. Diabetes Care. 2011;34(5):1171–6.
Vgontzas AN, et al. Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study. Diabetes Care. 2009;32(11):1980–5.
Budhiraja R, et al. Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep. 2011;34(7):859–67.
Innes KE, Selfe TK, Agarwal P. Restless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: a systematic review. Sleep Med Rev. 2011. Jul 4 [Epub ahead of print].
Allen RP, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101–19.
Dikeos D, Georgantopoulos G. Medical comorbidity of sleep disorders. Curr Opin Psychiatry. 2011;24(4):346–54.
Cuellar NG, Ratcliffe SJ. Restless legs syndrome in type 2 diabetes: implications to diabetes educators. Diabetes Educ. 2008;34(2):218–34.
Merlino G, et al. Association of restless legs syndrome in type 2 diabetes: a case–control study. Sleep. 2007;30(7):866–71.
Lopes LA, et al. Restless legs syndrome and quality of sleep in type 2 diabetes. Diabetes Care. 2005;28(11):2633–6.
Tasali E, et al. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA. 2008;105(3):1044–9.
Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest. 2010;137(1):95–101.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Holes-Lewis, K.A. (2012). Sleep Disturbances: Impact on Risk and Severity of Diabetes. In: Shiromani, P., Horvath, T., Redline, S., Van Cauter, E. (eds) Sleep Loss and Obesity. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3492-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3492-4_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3491-7
Online ISBN: 978-1-4614-3492-4
eBook Packages: MedicineMedicine (R0)